Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
My parents are both retired medical professionals who are in their early 70s. My father has diabetes that he manages with ...
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.
Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...
Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...